3,539 Shares in Zoetis Inc. $ZTS Bought by Verity & Verity LLC

Verity & Verity LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the second quarter, Holdings Channel.com reports. The firm acquired 3,539 shares of the company’s stock, valued at approximately $552,000.

Several other institutional investors have also modified their holdings of ZTS. Scott & Selber Inc. raised its position in shares of Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after purchasing an additional 67 shares during the last quarter. Secure Asset Management LLC boosted its stake in shares of Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after acquiring an additional 68 shares during the last quarter. Moment Partners LLC raised its stake in Zoetis by 3.2% in the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after purchasing an additional 72 shares during the last quarter. CVA Family Office LLC lifted its holdings in Zoetis by 6.7% in the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after purchasing an additional 74 shares in the last quarter. Finally, Menard Financial Group LLC boosted its stake in Zoetis by 3.8% during the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company’s stock worth $305,000 after purchasing an additional 75 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $124.86 on Tuesday. The company’s 50-day moving average is $137.28 and its two-hundred day moving average is $149.86. The firm has a market capitalization of $55.02 billion, a price-to-earnings ratio of 21.36, a PEG ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $181.85.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the previous year, the company earned $1.58 EPS. The business’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio is 33.67%.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research reports. BTIG Research dropped their target price on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. KeyCorp started coverage on shares of Zoetis in a research note on Thursday. They set a “sector weight” rating for the company. JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Argus restated a “buy” rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Finally, Stifel Nicolaus dropped their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Six equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Moderate Buy” and an average price target of $178.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.